• Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study on Lorlatinib for Patients with ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer Continuing from Previous Studies

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

  • Study on Guselkumab and Etanercept for Treating Chronic Plaque Psoriasis in Children Aged 6 to 17 Years

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Hungary Italy Poland

  • Study of Brentuximab Vedotin, Adriamycin, Vinblastine, and Dacarbazine for Children with Advanced Stage Hodgkin Lymphoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Italy

  • Study of Patritumab Deruxtecan with or without Endocrine Therapy for High-Risk HR+/HER2- Early Breast Cancer in Untreated Patients

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Apalutamide and Hormone Therapy Before Surgery for Patients with Advanced High-Risk Prostate Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +2

  • Study on the Safety and Effects of CPK850 Gene Therapy for Patients with Retinitis Pigmentosa Due to RLBP1 Gene Mutations

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on Immunosuppressive Therapies with Asfotase Alfa for Patients with Hypophosphatasia Experiencing Reduced Treatment Effectiveness

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Italy Poland Romania +1

powered by